Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off An announcement from Valneva ( (VALN) ) is now available. Valneva SE announced positive final results from its Phase 2 clinical trial for the chikungunya vaccine IXCHIQ® in children aged one to eleven years. The trial demonstrated that the vaccine was well tolerated and maintained high antibody levels twelve months post-vaccination, supporting the selection of a full dose for future Phase 3 trials. The strong immune response and favorable safety profile observed in children align with previous findings in adolescents and adults. The company plans to gather additional real-world data in adolescents before proceeding with Phase 3 trials in children, highlighting the importance of a long-term protective vaccine for chikungunya, especially in regions with limited vaccine access. The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page. Spark’s Take on VALN Stock According to Spark, TipRanks’ AI Analyst, VALN is a Neutral. Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns. To see Spark’s full report on VALN stock, click here. More about Valneva Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is involved in the development of vaccine candidates against global public health threats, including a Lyme disease vaccine candidate in partnership with Pfizer. Average Trading Volume: 41,683 Technical Sentiment Signal: Hold Current Market Cap: $761.3M